257 related articles for article (PubMed ID: 32395865)
1. Description of a large cohort of Caucasian patients with V122I ATTRv amyloidosis: Neurological and cardiological features.
Gentile L; Di Bella G; Minutoli F; Cucinotta F; Obici L; Mussinelli R; Arimatea I; Russo M; Toscano A; Vita G; Mazzeo A
J Peripher Nerv Syst; 2020 Sep; 25(3):273-278. PubMed ID: 32395865
[TBL] [Abstract][Full Text] [Related]
2. Association of the transthyretin variant V122I with polyneuropathy among individuals of African ancestry.
Parker MM; Damrauer SM; Tcheandjieu C; Erbe D; Aldinc E; Hawkins PN; Gillmore JD; Hull LE; Lynch JA; Joseph J; Ticau S; Flynn-Carroll AO; Deaton AM; Ward LD; Assimes TL; Tsao PS; Chang KM; Rader DJ; Fitzgerald K; Vaishnaw AK; Hinkle G; Nioi P
Sci Rep; 2021 Jun; 11(1):11645. PubMed ID: 34079032
[TBL] [Abstract][Full Text] [Related]
3. Neurological manifestations of hereditary transthyretin amyloidosis: a focus on diagnostic delays.
Kaku MC; Bhadola S; Berk JL; Sanchorawala V; Connors LH; Lau KHV
Amyloid; 2022 Sep; 29(3):184-189. PubMed ID: 35253562
[TBL] [Abstract][Full Text] [Related]
4. Comparison of cardiac involvement, extracardiac manifestations and outcomes between homozygote and heterozygote transthyretin p.Val142Ile (V122I) variant in patients with hereditary transthyretin amyloidosis: a cohort study.
Albenque G; Bézard M; Kharoubi M; Odouard S; Lunati A; Poullot E; Zaroui A; Teiger E; Hittinger L; Audard V; El Karoui K; Funalot B; Fanen P; Damy T; Oghina S
Amyloid; 2023 Dec; 30(4):407-415. PubMed ID: 37377439
[TBL] [Abstract][Full Text] [Related]
5. Association of the V122I Hereditary Transthyretin Amyloidosis Genetic Variant With Heart Failure Among Individuals of African or Hispanic/Latino Ancestry.
Damrauer SM; Chaudhary K; Cho JH; Liang LW; Argulian E; Chan L; Dobbyn A; Guerraty MA; Judy R; Kay J; Kember RL; Levin MG; Saha A; Van Vleck T; Verma SS; Weaver J; Abul-Husn NS; Baras A; Chirinos JA; Drachman B; Kenny EE; Loos RJF; Narula J; Overton J; Reid J; Ritchie M; Sirugo G; Nadkarni G; Rader DJ; Do R
JAMA; 2019 Dec; 322(22):2191-2202. PubMed ID: 31821430
[TBL] [Abstract][Full Text] [Related]
6. An additive destabilising effect of compound T60I and V122I substitutions in ATTRv amyloidosis.
Prokaeva T; Klimtchuk ES; Feschenko P; Spencer B; Cui H; Burks EJ; Aslebagh R; Muneeruddin K; Shaffer SA; Varghese E; Berk JL; Connors LH
Amyloid; 2023 Jun; 30(2):141-152. PubMed ID: 36286264
[TBL] [Abstract][Full Text] [Related]
7. Afro-Caribbean Heart Failure in the United Kingdom: Cause, Outcomes, and ATTR V122I Cardiac Amyloidosis.
Dungu JN; Papadopoulou SA; Wykes K; Mahmood I; Marshall J; Valencia O; Fontana M; Whelan CJ; Gillmore JD; Hawkins PN; Anderson LJ
Circ Heart Fail; 2016 Sep; 9(9):. PubMed ID: 27618855
[TBL] [Abstract][Full Text] [Related]
8. Low Prevalence of Clinically Apparent Cardiac Amyloidosis Among Carriers of Transthyretin V122I Variant in a Large Electronic Medical Record.
Agbor-Etang BB; Okafor HE; Farber-Eger EH; Wells QS
Am J Med; 2021 Feb; 134(2):e98-e100. PubMed ID: 32866461
[TBL] [Abstract][Full Text] [Related]
9. Same same, but different? The neurological presentation of wildtype transthyretin (ATTRwt) amyloidosis.
Kleefeld F; Scherret E; Knebel F; Messroghli D; Heidecker B; Wetz C; Schatka I; Barzen G; Tschöpe C; Amthauer H; Hahn K
Amyloid; 2022 Jun; 29(2):92-101. PubMed ID: 34994254
[TBL] [Abstract][Full Text] [Related]
10. Phenotypes Associated With the Val122Ile, Leu58His, and Late-Onset Val30Met Variants in Patients With Hereditary Transthyretin Amyloidosis.
Zampino S; Sheikh FH; Vaishnav J; Judge D; Pan B; Daniel A; Brown E; Ebenezer G; Polydefkis M
Neurology; 2023 May; 100(19):e2036-e2044. PubMed ID: 36941075
[TBL] [Abstract][Full Text] [Related]
11. Characterization and natural history of different phenotypes in hereditary transthyretin amyloidosis: 40-year experience at a single Italian referral centre.
Caponetti AG; Sguazzotti M; Accietto A; Saturi G; Ponziani A; Giovannetti A; Massa P; Ruotolo I; Sena G; Zaccaro A; Parisi V; Bonfiglioli R; Guaraldi P; Gagliardi C; Cortelli P; Galie N; Biagini E; Longhi S
Eur J Prev Cardiol; 2024 May; 31(7):866-876. PubMed ID: 38204330
[TBL] [Abstract][Full Text] [Related]
12. Hereditary transthyretin-related amyloidosis is frequent in polyneuropathy and cardiomyopathy of no obvious aetiology.
Skrahina V; Grittner U; Beetz C; Skripuletz T; Juenemann M; Krämer HH; Hahn K; Rieth A; Schaechinger V; Patten M; Tanislav C; Achenbach S; Assmus B; Knebel F; Gingele S; Skrahin A; Hartkamp J; Förster TM; Roesner S; Pereira C; Rolfs A
Ann Med; 2021 Dec; 53(1):1787-1796. PubMed ID: 34658264
[TBL] [Abstract][Full Text] [Related]
13. Genetic screening for hereditary transthyretin amyloidosis with polyneuropathy in western Sicily: Two years of experience in a neurological clinic.
Di Stefano V; Lupica A; Alonge P; Pignolo A; Augello SM; Gentile F; Gagliardo A; Giglia F; Brinch D; Cappello M; Di Lisi D; Novo G; Borgione E; Scuderi C; Brighina F
Eur J Neurol; 2024 Jan; 31(1):e16065. PubMed ID: 37725003
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of
Lopes LR; Futema M; Akhtar MM; Lorenzini M; Pittman A; Syrris P; Elliott PM
Amyloid; 2019 Dec; 26(4):243-247. PubMed ID: 31554435
[No Abstract] [Full Text] [Related]
15. Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy.
Porcari A; Razvi Y; Masi A; Patel R; Ioannou A; Rauf MU; Hutt DF; Rowczenio D; Gilbertson J; Martinez-Naharro A; Venneri L; Whelan C; Lachmann H; Wechalekar A; Quarta CC; Merlo M; Sinagra G; Hawkins PN; Fontana M; Gillmore JD
Eur J Heart Fail; 2023 Apr; 25(4):515-524. PubMed ID: 36644836
[TBL] [Abstract][Full Text] [Related]
16. Diagnosis and treatment of hereditary transthyretin amyloidosis with polyneuropathy in the United States: Recommendations from a panel of experts.
Karam C; Mauermann ML; Gonzalez-Duarte A; Kaku MC; Ajroud-Driss S; Brannagan TH; Polydefkis M
Muscle Nerve; 2024 Mar; 69(3):273-287. PubMed ID: 38174864
[TBL] [Abstract][Full Text] [Related]
17. Identification of Transthyretin Cardiac Amyloidosis Using Serum Retinol-Binding Protein 4 and a Clinical Prediction Model.
Arvanitis M; Koch CM; Chan GG; Torres-Arancivia C; LaValley MP; Jacobson DR; Berk JL; Connors LH; Ruberg FL
JAMA Cardiol; 2017 Mar; 2(3):305-313. PubMed ID: 28196196
[TBL] [Abstract][Full Text] [Related]
18. Neurofilament light chain, a biomarker for polyneuropathy in systemic amyloidosis.
Louwsma J; Brunger AF; Bijzet J; Kroesen BJ; Roeloffzen WWH; Bischof A; Kuhle J; Drost G; Lange F; Kuks JBM; Gans ROB; Hazenberg BPC; Nienhuis HLA
Amyloid; 2021 Mar; 28(1):50-55. PubMed ID: 32883119
[TBL] [Abstract][Full Text] [Related]
19. ATTRv amyloidosis Italian Registry: clinical and epidemiological data.
Russo M; Obici L; Bartolomei I; Cappelli F; Luigetti M; Fenu S; Cavallaro T; Chiappini MG; Gemelli C; Pradotto LG; Manganelli F; Leonardi L; My F; Sampaolo S; Briani C; Gentile L; Stancanelli C; Di Buduo E; Pacciolla P; Salvi F; Casagrande S; Bisogni G; Calabrese D; Vanoli F; Di Iorio G; Antonini G; Santoro L; Mauro A; Grandis M; Di Girolamo M; Fabrizi GM; Pareyson D; Sabatelli M; Perfetto F; Rapezzi C; Merlini G; Mazzeo A; Vita G
Amyloid; 2020 Dec; 27(4):259-265. PubMed ID: 32696671
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal analysis of serum neurofilament light chain levels as marker for neuronal damage in hereditary transthyretin amyloidosis.
Berends M; Brunger AF; Bijzet J; Kroesen BJ; Drost G; Lange F; Teunissen CE; In 't Veld S; Vrancken AF; Gans ROB; Hazenberg BPC; van der Zwaag PA; Nienhuis HLA
Amyloid; 2024 Jun; 31(2):132-141. PubMed ID: 38477065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
